Investors & Share Price Information
Bachem offers strong growth potential as a leader in peptides and oligonucleotides, backed by innovation, scalability, and a long‑term commitment to value creation.
Stock market information
Track Bachem’s performance in real time with our live, interactive stock graph.
Upcoming financial events
Corporate Governance
Bachem’s corporate governance is grounded in clarity, responsibility, and a commitment to ethical behavior. Our shareholder‑elected Board of Directors sets the strategic direction of the company and provides guidance for long‑term value creation. The Corporate Executive Committee ensures this strategy is translated into action by managing global operations and driving excellence across all functions. At the foundation of our culture stands the Bachem Code of Conduct, which defines how we act every day - ensuring integrity, compliance, and responsible decision‑making throughout the organization.
Sign up for our financial news
Analyst Coverage
As a stock listed company, Bachem is as a company reviewed and commented upon by analysts on a regular basis. According to our best knowledge, the hereunder mentioned finance institutions prepare and issue Bachem related reports. There is no guarantee regarding the completeness and correctness of the list, although we strive to maintain and update it. Bachem does not comment on any analyst report and disclaims any liability in relation with statements or recommendations made therein as well as transactions based thereon.
|
Baader Helvea AG
|
Wiechert Konstantin
|
|
|
|
Barclays
|
Charles Pitman-King
CFA | European Pharmaceuticals |
|
|
|
Berenberg Bank
|
Estelle Bétrisey
|
|
|
|
Deutsche Bank
|
Fynn Scherzler
|
|
|
|
Jefferies
|
Christopher Richardson
|
|
|
|
J.P. Morgan
|
Zain Ebrahim
VP EMEA Equity Research European Pharma & Biotech |
|
|
|
Octavian AG
|
Laura Pfeifer-rRossi
|
|
|
|
Research Partners AG
|
Dr. Martin Vögtli
|
|
|
|
Royal Bank of Canada Europe Ltd
|
Charles Weston, CFA
Director, European Healthcare Equity Research |
|
|
|
UBS
|
Tanya Hansalik
|
|
|
|
Vontobel
|
Sibylle Bischofberger
Senior Analyst Equity Research |
|
|
|
Zürcher Kantonalbank
|
Daniel Jelovcan
Senior Equity Analyst Medical Technology & CDMO Research |
|
|
|
ODDO BHF Asset Management
|
Stephan Wulf
|
|
|
Your investor relations contact
Barbora Blaha
Head of Investor Relations